Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Orlistat | Orlistat can cause a decrease in the absorption of Menadione bisulfite resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alpha-1-proteinase inhibitor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione bisulfite. |
| Menadione | Menadione may increase the thrombogenic activities of Menadione bisulfite. |
| Tranexamic acid | Tranexamic acid may increase the thrombogenic activities of Menadione bisulfite. |
| Aminocaproic acid | Aminocaproic acid may increase the thrombogenic activities of Menadione bisulfite. |
| Aprotinin | Aprotinin may increase the thrombogenic activities of Menadione bisulfite. |
| Hydrogen peroxide | Hydrogen peroxide may increase the thrombogenic activities of Menadione bisulfite. |
| Aminomethylbenzoic acid | Aminomethylbenzoic acid may increase the thrombogenic activities of Menadione bisulfite. |
| Camostat | Camostat may increase the thrombogenic activities of Menadione bisulfite. |
| Fibrinogen human | The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Menadione bisulfite. |
| Tretinoin | The risk or severity of Thrombosis can be increased when Menadione bisulfite is combined with Tretinoin. |
| Antihemophilic factor, human recombinant | Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor, human recombinant. |
| Coagulation factor VIIa Recombinant Human | Menadione bisulfite may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human. |
| Coagulation Factor IX (Recombinant) | Menadione bisulfite may increase the thrombogenic activities of Coagulation Factor IX (Recombinant). |
| Calcium | Menadione bisulfite may increase the thrombogenic activities of Calcium. |
| Pantothenic acid | Menadione bisulfite may increase the thrombogenic activities of Pantothenic acid. |
| Formic acid | Menadione bisulfite may increase the thrombogenic activities of Formic acid. |
| Platelet Activating Factor | Menadione bisulfite may increase the thrombogenic activities of Platelet Activating Factor. |
| Turoctocog alfa | Menadione bisulfite may increase the thrombogenic activities of Turoctocog alfa. |
| Catridecacog | Menadione bisulfite may increase the thrombogenic activities of Catridecacog. |
| Antihemophilic factor (recombinant), PEGylated | Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated. |
| Prothrombin | Menadione bisulfite may increase the thrombogenic activities of Prothrombin. |
| Factor IX Complex (Human) | Menadione bisulfite may increase the thrombogenic activities of Factor IX Complex (Human). |
| Susoctocog alfa | Menadione bisulfite may increase the thrombogenic activities of Susoctocog alfa. |
| Eftrenonacog alfa | Menadione bisulfite may increase the thrombogenic activities of Eftrenonacog alfa. |
| Rusalatide acetate | Menadione bisulfite may increase the thrombogenic activities of Rusalatide acetate. |
| Vatreptacog alfa | Menadione bisulfite may increase the thrombogenic activities of Vatreptacog alfa. |
| Factor XIII (human) | Menadione bisulfite may increase the thrombogenic activities of Factor XIII (human). |
| Von Willebrand factor human | Menadione bisulfite may increase the thrombogenic activities of Von Willebrand factor human. |
| Coagulation factor X human | Menadione bisulfite may increase the thrombogenic activities of Coagulation factor X human. |
| Coagulation factor VII human | Menadione bisulfite may increase the thrombogenic activities of Coagulation factor VII human. |
| Anti-inhibitor coagulant complex | Menadione bisulfite may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Coagulation Factor IX Human | Menadione bisulfite may increase the thrombogenic activities of Coagulation Factor IX Human. |
| Antihemophilic factor human | Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor human. |
| Kallidinogenase | Menadione bisulfite may increase the thrombogenic activities of Kallidinogenase. |
| Trenonacog alfa | Menadione bisulfite may increase the thrombogenic activities of Trenonacog alfa. |
| Albutrepenonacog alfa | Menadione bisulfite may increase the thrombogenic activities of Albutrepenonacog alfa. |
| Emicizumab | Menadione bisulfite may increase the thrombogenic activities of Emicizumab. |
| Nonacog beta pegol | Menadione bisulfite may increase the thrombogenic activities of Nonacog beta pegol. |
| Moroctocog alfa | Menadione bisulfite may increase the thrombogenic activities of Moroctocog alfa. |
| Beroctocog alfa | Menadione bisulfite may increase the thrombogenic activities of Beroctocog alfa. |
| Andexanet alfa | Menadione bisulfite may increase the thrombogenic activities of Andexanet alfa. |
| Calcium cation | Menadione bisulfite may increase the thrombogenic activities of Calcium cation. |
| Damoctocog alfa pegol | Menadione bisulfite may increase the thrombogenic activities of Damoctocog alfa pegol. |
| Turoctocog alfa pegol | Menadione bisulfite may increase the thrombogenic activities of Turoctocog alfa pegol. |
| Alteplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Tenecteplase. |
| Streptokinase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Streptokinase. |
| Lanoteplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Lanoteplase. |
| Amediplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Amediplase. |
| Saruplase | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Saruplase. |
| Protein S human | Menadione bisulfite may increase the thrombogenic activities of Protein S human. |
| Rurioctocog alfa pegol | Menadione bisulfite may increase the thrombogenic activities of Rurioctocog alfa pegol. |
| Etranacogene dezaparvovec | Menadione bisulfite may increase the thrombogenic activities of Etranacogene dezaparvovec. |